MCGRAW TRIAL: EVALUATION OF THE SAFETY AND EFFICACY OF AN ORAL MICROBIAL INTERVENTION (SER-401) IN COMBINATION WITH NIVOLUMAB IN FIRST LINE METASTATIC MELANOMA PATIENTS

1Isabella Giltza Oliva, 2Omid Hamid, 3Patrick Ott, 4Genevieve Boland, 4Ryan Sullivan, 5Kenneth Grossmann, 6Christopher Desjardins, 6Nathan Hicks, 4Brian Weiner, 4Farah Alayli, 5Farah Alayli, 1Christine Spencer, 6Shikha Guatam, 7Christopher Loo, 2Benjamin Kamphaus, 2Julie Densmore, 2Christopher Cabanski, 6Diane Da Silva, 2Jennifer Wargo, 2Justin Faich, 7Marko Spasic, 2John Aunins, 6Kelly Brady, 1Elizabeth Burton, 6Jennifer Wortman, 7Julie Densmore, 2Mathew Henn, 1Hussein Tabbi, 1The University of Texas MD Anderson Cancer Center, Houston, TX, United States; 7Theresa LaVallee, 2Mathew Henn, 1Hussein Tabbi, 1The University of Texas MD Anderson Cancer Center, Houston, TX, United States; 2Angeles Clinic and Research Institute, Los Angeles, CA, United States; 3Dana-Farber Cancer Institute, Boston, MA, United States; 4Mass General Cancer Center, Boston, MA, United States; 5Huntsman Cancer Institute, Salt Lake City, UT United States; 6Seres Therapeutics, Cambridge, MA, United States; 7Parker Institute for Cancer Immunotherapy, San Francisco, CA, United States

Background While anti-PD-based therapy is an approved first-line treatment for patients with advanced, surgically unresectable metastatic melanoma (MM), many do not benefit. Abundance of Ruminococcaceae and other microbes in cancer patients’ gut microbiome has been associated with improved anti-PD1 efficacy. Thus, combination approaches to overcome anti-PD1 primary resistance with gut microbiome modulation are being explored. In this trial, SER-401, an investigational microbiome therapeutic enriched in Ruminococcaceae and other spore-forming microbes, was evaluated in combination with nivolumab in first line MM patients.

Methods MCGRAW is a multi-center, randomized, blinded, and placebo-controlled phase Ib study in patients with advanced melanoma. Patients were randomized 2:1 to the SER-401 active or placebo arm, respectively, and stratified by baseline stool Ruminococcaceae abundance. Patients received an oral vancomycin preparative regimen+SER-401 (active arm), versus no antibiotics+placebo (placebo arm). One week later, all patients received nivolumab 480 mg Q4W. The primary endpoint was safety. Secondary endpoints were SER-401 microbiome engraftment, ORR, DCR, PFS, and change in frequency of tumoral CD8+ T cells on-treatment. The study was not powered for comparison between arms. Baseline and on-treatment stool samples were collected for microbiome analysis, tumor and blood samples were collected for exploratory biomarker analysis.

Results Fourteen patients were randomized (N=8 active, N=6 placebo). Grade 3-4 TRAEs were observed in 0 and 1 (17%) participants in the SER-401/nivolumab and placebo/nivolumab arms, respectively. In the vancomycin+SER-401/nivolumab arm, ORR was 25.0% (95% CI: 3-63) and DCR was 37.5% (95% CI: 9-76). In the no antibiotics+placebo/nivolumab arm, ORR was 66.7% (95% CI: 22-96) and DCR was 83.3% (95% CI: 36-99). Overall, microbiome engraftment was observed in the active arm but did not reach optimal kinetics or magnitude in many patients. Differences in the fecal microbial and metabolic profiles of responders and non-responders were observed to be prior to initial nivolumab administration. Additional orthogonal biomarker analyses revealed further differences between the responders and non-responders, with the CR patient in the active arm having a distinct profile both at screening and on-treatment.

Conclusions This study demonstrated that SER-401 and anti-PD1 are a safe combination in MM patients, however DCR was lower in the active arm versus control, perhaps related to the antibiotic preparative regimen. Enrollment challenges and sub-optimal SER-401 engraftment resulted in early termination of the study. Despite these limitations, our integrative clinical and biomarker analysis provides information regarding the link between the gut microbiome, peripheral immune cell populations, and the tumor microenvironment during nivolumab therapy with or without SER-401.

Acknowledgements We extend our gratitude to the patients, their families, the clinical investigators, and their site staff members who made this trial possible. We would also like to thank Sultan Nawabi at Parker Institute for Cancer Immunotherapy (PICI) for operations leadership of the trial. The study was funded by Seres Therapeutics.

Trial Registration ClinicalTrials.gov (NCT03817125)

Ethics Approval The MCGRAW study was approved by WCG IRB (previously known as WIRB) protocol # 20182747

Consent All participants provided written informed consent before enrollment